Eversept Partners, LP Biomarin Pharmaceutical Inc Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $7.91 Million - $8.91 Million	-84,257 Closed	0 $0
Q2 2018 Nov 08, 2023	BUY	$76.01 - $99.03 $2.91 Million - $3.79 Million	38,257 Added 83.17%	84,257 $7.94 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $2.91 Million - $3.79 Million	38,257 Added 83.17%	84,257 $7.94 Million
Q1 2018 Nov 08, 2023	BUY	$77.67 - $92.63 $3.57 Million - $4.26 Million	46,000 New	46,000 $3.73 Billion
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $23,301 - $27,789	300 Added 0.66%	46,000 $3.73 Million
Q4 2017 Nov 08, 2023	BUY	$80.76 - $95.13 $3.69 Million - $4.35 Million	45,700 New	45,700 $4.08 Billion
Q4 2017 Feb 12, 2018	BUY	$80.76 - $95.13 $3.69 Million - $4.35 Million	45,700	45,700 $4.08 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.